ReviewJACC. CardioOncology2021
Cardiac Computed Tomography in Cardio-Oncology:
Review in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC.European heart journal. Cardiovascular Imaging · 2026Review
- Cardiovascular Imaging for the Early Detection of Cardiotoxicity from Emerging Cancer Therapies: Mechanistic Insights Across the Pediatric and Adult Spectrum.Journal of personalized medicine · 2026Review
- Diagnostics in cardio-oncology: a focus on anthracyclines.Heart failure reviews · 2026Review
- Advancing cardiac tumor diagnosis: evaluatingAmerican journal of cardiovascular disease · 2026Review
- Effects of Exercise on Cardiovascular and Metabolic Responses in Adults and Childhood Cancer Survivors: The Role of NETosis and Low-Grade Inflammation as a Novel Therapeutic Target-A Narrative Review.International journal of molecular sciences · 2025Review
- Cancer-Induced Cardiac Dysfunction: Mechanisms, Diagnostics, and Emerging Therapeutics in the Era of Onco-Cardiology.Cancers · 2025Review
- Serial assessment of coronary artery inflammation using cardiac CT in anthracycline chemotherapy for breast cancer.European radiology · 2025Article
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
- Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses:JACC. CardioOncology · 2024Review
- Anthracycline Cardiotoxicity in Adult Cancer Patients:JACC. CardioOncology · 2024Review
- Review
- Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology.Journal of cardiovascular imaging · 2024Review
- Overall approaches to cardiac tumors: Still an unsolved enigma?World journal of clinical cases · 2024Article
- Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.International journal of molecular sciences · 2024Review
- Multimodality imaging approach in a case of vascular toxicity caused by cabozantinib.Radiology case reports · 2024Article
- Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy.Life (Basel, Switzerland) · 2023Review
- Multimodality imaging in cardio-oncology: the added value of CMR and CCTA.The British journal of radiology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
Abstract
Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosclerotic cardiovascular disease (ASCVD), valvular heart disease, pericardial disease, and arrhythmias. Cardiac computed tomography (CT) can be helpful in identifying both clinical and subclinical ASCVD in cancer patients and survivors. Radiation therapy treatment planning CT scans and cancer staging/re-staging imaging studies can quantify calcium scores which can identify pre-existing subclinical ASCVD. Cardiac CT can be helpful in the evaluation of cardiac tumors and pericardial diseases, especially in patients who cannot tolerate or have a contraindication to cardiac magnetic resonance. In this review, we describe the optimal utilization of cardiac CT in cancer patients, including risk assessment for ASCVD and identification of cancer treatment-related cardiovascular toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.